Study identifier:D5130R00029
ClinicalTrials.gov identifier:NCT02408224
EudraCT identifier:N/A
CTIS identifier:N/A
A non-interventional prospective observational study to understand the usage pattern of Ticagrelor in Indian patients with acute coronary syndrome.
Acute Coronary Syndrome
N/A
No
-
All
3000
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2018 by AstraZeneca
AstraZeneca
-
The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India. The aim of this national study is to understand the usage pattern (including the duration of treatment) of Ticagrelor in various ACS patient population undergoing PCI (Percutaneous Coronary Intervention), CABG (Coronary Artery Bypass Graft) or medical management in a real-life setting in India.
This study is a multi-centre, observational, prospective study to be conducted at 60 hospitals across IndiaThe study will be initiated after obtaining written approval of Independent Ethics Committee (IEC) and written Informed consent of the patient. Patients who had been hospitalized for ACS and are on ticagrelor on discharge or on Ticagrelor therapy for ≤ 1month will be enrolled in the study and followed up for a period of 12 months. During the follow-up period of up to 12 months (according to the label), assessment visits will follow the routine clinical practice. No visits or measurements will be made mandatory by the protocol
Location
Location
Delhi, New Delhi, India
Location
Mumbai, Maharashtra, India
Location
Chennai, Tamil Nadu, India
Location
Kolkata, West Bengal, India
Location
Surat, Gujarat, India
Location
Ludhiana, Punjab, India
Location
Noida, Uttar Pradesh, India
Location
Rajkot, Gujarat, India
Arms | Assigned Interventions |
---|---|
one arm patients on Ticagrelor | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.